Chronic Idiopathic Constipation Treatment Market

Chronic Idiopathic Constipation Treatment Market (Drug Class: Serotonin-4 [5-Ht4] Receptor Agonist, Guanylate Cyclase-C Agonist, Laxatives, Stimulants, and Others; Route of Administration: Oral and Rectal; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030(CIC) Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2020 - 2030

Market Players Focus on Improving Existing Chronic Idiopathic Constipation Therapies

Chronic idiopathic constipation is a highly prevalent functional bowel disorder that affects millions of individuals worldwide. Some of the major factors that contribute to the burgeoning number of patients suffering from chronic idiopathic constipation include sedentary lifestyle, increasing usage of anti-inflammatory agents, and drastic decline in the intake of dietary fibers. Over the past few years, considerable efforts have been made to improve the management of chronic idiopathic constipation. In the current scenario, empiric therapy has garnered considerable attention from the stakeholders operating in the current chronic idiopathic constipation treatment market – a trend that is expected to continue during the forecast period.

Researchers involved in the current chronic idiopathic constipation treatment market landscape are also increasingly focusing on the development of customized treatment plans that offer multi-symptom relief. Efforts are being made to improve the efficacy of the current therapeutic agents due to which, a steady growth of the global chronic idiopathic constipation treatment market is anticipated in the upcoming years. A number of players involved in the current market for chronic idiopathic constipation treatment are focusing on gaining approval from the FDA for the newly developed drugs and treatments.

At the back of these factors, along with the augmenting demand for chronic idiopathic constipation treatment, the global chronic idiopathic constipation treatment market is expected to surpass the US$ 15.9 Bn mark by the end of 2030.

Request a sample to get extensive insights into the Chronic Idiopathic Constipation Treatment Market

Consistent Progress in Management of Chronic Idiopathic Constipation to Bolster Market Growth

In the initial stages, chronic idiopathic constipation treatment primarily included a blend of medication review, lifestyle modifications, and patient education. While prescription treatments are expected to witness considerable adoption worldwide, a number of non-prescription chronic idiopathic constipation treatments, including fiber supplementation, has garnered popularity. Moreover, research activities suggest that soluble fibers such as psyllium offer relief to patients suffering from chronic idiopathic constipation in comparison with insoluble fibers including bran. The increasing usage of soluble fibers has led to a noteworthy improvement in global symptoms and stool consistency due to which, the chronic idiopathic constipation treatment market is largely leaning toward the utilization of soluble fibers in the empiric fiber therapy. The rising usage of osmotic laxatives, stimulant laxative, and bulking laxatives is expected to contribute to the growth of the global chronic idiopathic constipation treatment market as the demand for non-prescription treatments continues to move in the upward trajectory.

While non-prescription treatments are gradually gaining worldwide adoption, the demand for prescription treatments is on the rise. However, players operating in the current chronic idiopathic constipation treatment market landscape are increasingly focusing on catering to the unmet needs with existing chronic idiopathic constipation treatment alternatives.

Unpredictability, poor symptom relief, bloating, and inability to enhance the quality of life of current treatments have compelled companies in the current market for chronic idiopathic constipation treatment to introduce better prescription agents and mechanisms. Some of the recently developed prescription agents that are gaining fast-paced adoption include prosecretory agents and a host of FDA approved products such as linaclotide.

To understand how our report can bring difference to your business strategy, Ask for a brochure

FDA Approval of New Drugs to Aid Market Growth

In the current scenario, manufacturers operating in the chronic idiopathic constipation treatment market are increasingly seeking the approval of the FDA for their newly developed drugs. Gaining the approval of the FDA is expected to remain one of the core areas of focus for the chronic idiopathic constipation drug manufacturers over the course of the forecast period. A number of drugs has received the green signal from the FDA in recent years.

In February 2020, the U.S. FDA approved an osmotic laxative developed by the Braintree Laboratories to treat chronic idiopathic constipation among adults. While attaining the FDA approval is expected to remain a top priority, market players are likely to increase the R&D spending on the development of new therapeutics and products.

Moderate Impact of COVID-19 Pandemic on Global Market

The onset of the COVID-19 pandemic is expected to have a moderate impact on the global chronic idiopathic constipation treatment market in 2020. The first quarter of 2020 witnessed steady ascension in the demand for chronic idiopathic constipation treatment worldwide. However, outbreak of the COVID-19 pandemic toward the end of the first quarter and stringent lockdown measures implemented by governments in the second and the third quarter of 2020 are expected to negatively affect the adoption of chronic idiopathic constipation treatment. However, the demand is set to witness considerable growth toward the end of 2020, as governments around the world continue to lift the lockdown measures in a phased manner.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Chronic Idiopathic Constipation Treatment Market

Analysts’ Viewpoint

The global chronic idiopathic constipation treatment market is expected to grow at a healthy CAGR of ~7% during the forecast period. The market growth can be primarily attributed to factors such as increasing prevalence of chronic idiopathic constipation among adults worldwide, high demand for improved chronic idiopathic constipation treatment and therapies to address unmet needs of existing treatments, and research and development activities. Market players should focus on the development of new prescription as well as non-prescription chronic idiopathic constipation treatments and continue to invest in R&D activities.

Chronic Idiopathic Constipation Treatment Market: Overview

  • According to Transparency Market Research’s latest report on the global chronic idiopathic constipation treatment market for the historical period 2018–2019 and forecast period 2020–20230, promising pipeline is anticipated to drive the global m chronic idiopathic constipation treatment market
  • Constipation is a highly common chronic gastrointestinal disorder. Chronic idiopathic constipation (CIC) is a health condition in which a patient experiences chronic symptoms of constipation. Changing dietary habits, i.e., reduction in fluid and fiber intake in diet, changes in water balance, and changes in contractility of the colon cause chronic idiopathic constipation.

Increase in Demand for CIC Treatment Products to Drive Chronic Idiopathic Constipation Treatment Market

  • Steady rise in prevalence of constipation across the global population is leading to high demand for newer therapeutics. This, in turn, is estimated to drive the market. Healthcare providers and patients both report unmet needs with current chronic idiopathic constipation treatment options.
  • Around 50% of patients with chronic idiopathic constipation report dissatisfaction with non-prescription laxatives due to unpredictability, bloating, poor symptom relief, or inability to improve quality of life. Alternative agents with novel mechanisms of action are being developed for the last 10 years in order to address these concerns.
  • Likewise, several of the available specialty drugs are intended for use in adolescents and adult patients. Surge in incidence of constipation among children is likely to present significant opportunities for key players and new entrants to develop and launch specialty constipation drugs for pediatric use.

Rise in Healthcare Spending and Improvements in Healthcare Infrastructure Propel Chronic Idiopathic Constipation Treatment Market

  • Increase in the number of patients with chronic idiopathic constipation boosts adoption of newer products. Patients are more aware and proactive about their health, and are willing to seek effective treatment. Hence, rise in healthcare spending on constipation is likely to boost the market.
  • An article published in the American Journal of Managed Care in 2007 stated that people in the U.S. spent more than US$ 800 million on laxatives. Chronic idiopathic constipation has a significant impact on the healthcare system, and it accounted for 3.92% of all ambulatory care visits in the U.S. in 2014.

High Cost to Hamper Chronic Idiopathic Constipation Treatment Market

  • Chronic idiopathic constipation continues to be associated with significant costs. It is like numerous other common conditions that contribute to greater morbidity and healthcare costs.
  • An article published in the American Journal of Managed Care stated that around 81% of cost of chronic idiopathic constipation treatment is associated with the use of medical services, including visits to prescribers and outpatient services. It is reported that pharmacy costs for chronic constipation patients with abdominal symptoms is 1.6 times higher than patients who did not have abdominal symptoms.
  • Cost of treatment is an important concern regarding the selection of treatment. Hence, higher cost associated with treatment hampers the market. For instance, the annual cost of treatment of chronic idiopathic constipation ranges from US$ 1,912 to US$ 7,522 per patient. In the U.S., direct medical cost of medical constipation is estimated at US$ 230 million per year.

Chronic Idiopathic Constipation Treatment Market: Competition Landscape

  • This report profiles major players operating in the global chronic idiopathic constipation treatment market based on various attributes and recent developments
  • The global chronic idiopathic constipation treatment market is highly fragmented with the presence of numerous global as well as regional players
  • Leading players operating in the global chronic idiopathic constipation treatment market include
    • Bayer AG
    • Allergan
    • Bausch Health
    • Sanofi
    • Takeda Pharmaceutical Company
    • SEBELA PHARMACEUTICALS
    • Ironwood Pharmaceuticals, Inc.
    • Albireo Pharma, Inc.
    • Sucampo Pharmaceuticals, Inc. (Mallinckrodt)
    • Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

Chronic Idiopathic Constipation Treatment Market: Key Developments

  • Key players in the global chronic idiopathic constipation treatment market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are aimed at addressing unmet needs in the chronic idiopathic constipation treatment market, strengthening the product portfolio, and investing in research & development.
  • A few expansion strategies adopted by players operating in the global chronic idiopathic constipation treatment market are:
  • In April 2020, Ironwood Pharmaceuticals, Inc. announced that the USPTO (United States Patent and Trademark) issued Notices of Allowance for patent applications covering the formulation of the 72 mcg dose of LINZESS
  • In March 2020, SEBELA PHARMACEUTICALS received approval from the U.S. Food and Drug Administration for Pizensy (lactitol). This approval represents a step forward in the treatment options for CIC.
  •  In September 2019, Ironwood Pharmaceuticals, Inc. entered into an amended collaboration agreement with AstraZeneca for the development and commercialization of LINZESS, in China
  • In February 2018, Mallinckrodt acquired Sucampo. Sucampo's primary commercialized product was Amitiza, a leading global product in the branded constipation market
  • The report on the global chronic idiopathic constipation treatment market discussed individual strategies, followed by company profiles of manufacturers of chronic idiopathic constipation treatment products. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global chronic idiopathic constipation treatment market.

Chronic Idiopathic Constipation Treatment Market – Segmentation

Drug Class

  • Serotonin-4 (5-Ht4) Receptor Agonist
    • Prucalopride
    • Others
  • Guanylate Cyclase-C Agonist
    • Plecanatide
    • Linaclotide     
  • Laxatives
    • Sodium Picosulphate
    • Polycarbophil
    • Others
  • Stimulants
    • Bisacodyl
    • Senokot
    • Others
  • Others

Route of Administration

  • Oral
  • Rectal

Distribution Channel

  • Hospital Pharmacies   
  • Retail Pharmacies       
  • Online Pharmacies     

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of chronic idiopathic constipation treatment market?

Chronic Idiopathic Constipation Treatment Market to surpass valuation of US$ 15.9 Bn by 2030

What is the anticipated CAGR of the chronic idiopathic constipation treatment market in the forecast period?

Chronic Idiopathic Constipation Treatment Market is projected to expand at a CAGR of ~7% from 2020 to 2030

What are the key driving factors for the growth of the chronic idiopathic constipation treatment market?

Chronic Idiopathic Constipation Treatment Market is driven by increase in R&D activities and expenditure on new products and therapeutics development

Which region is expected to project the highest market share in the global chronic idiopathic constipation treatment market?

North America accounted for major share of the global chronic idiopathic constipation treatment market and the trend is anticipated to continue during the forecast period

Who are the key players in the global chronic idiopathic constipation treatment market?

Key players in the global chronic idiopathic constipation treatment market include Bayer AG, Allergan, Bausch Health, Sanofi, Takeda Pharmaceutical Company

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Chronic Idiopathic Constipation Treatment Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Drug Class Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, 2018–2030

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

        5.3. Diseases Prevalence by Global/Sub-region

        5.4. Key Developments

    6. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, by Drug Class

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            6.3.1. Serotonin-4 (5-Ht4) Receptor Agonist

                6.3.1.1. Prucalopride

                6.3.1.2. Others

            6.3.2. Guanylate Cyclase-C Agonist

                6.3.2.1. Plecanatide

                6.3.2.2. Linaclotide

            6.3.3. Laxatives

                6.3.3.1. Sodium Picosulphate

                6.3.3.2. Polycarbophil

                6.3.3.3. Others

            6.3.4. Stimulants

                6.3.4.1. Bisacodyl

                6.3.4.2. Senokot

                6.3.4.3. Others

            6.3.5. Others

        6.4. Global Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class

    7. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, by Route of Administration

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

            7.3.1. Oral

            7.3.2. Rectal

        7.4. Global Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration

    8. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            8.3.1. Hospital Pharmacies

            8.3.2. Retail Pharmacies

            8.3.3. Online Pharmacies

        8.4. Global Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel

    9. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Global Chronic Idiopathic Constipation Treatment Market Attractiveness, by Region

    10. North America Chronic Idiopathic Constipation Treatment Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            10.2.1. Serotonin-4 (5-Ht4) Receptor Agonist

                10.2.1.1. Prucalopride

                10.2.1.2. Others

            10.2.2. Guanylate Cyclase-C Agonist

                10.2.2.1. Plecanatide

                10.2.2.2. Linaclotide

            10.2.3. Laxatives

                10.2.3.1. Sodium Picosulphate

                10.2.3.2. Polycarbophil

                10.2.3.3. Others

            10.2.4. Stimulants

                10.2.4.1. Bisacodyl

                10.2.4.2. Senokot

                10.2.4.3. Others

            10.2.5. Others

        10.3. North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

            10.3.1. Oral

            10.3.2. Rectal

        10.4. North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            10.4.1. Hospital Pharmacies

            10.4.2. Retail Pharmacies

            10.4.3. Online Pharmacies

        10.5. North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country, 2018–2030

            10.5.1. U.S.

            10.5.2. Canada

        10.6. North America Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis

            10.6.1. By Drug Class

            10.6.2. By Route of Administration

            10.6.3. By Distribution Channel

            10.6.4. By Country

    11. Europe Chronic Idiopathic Constipation Treatment Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            11.2.1. Serotonin-4 (5-Ht4) Receptor Agonist

                11.2.1.1. Prucalopride

                11.2.1.2. Others

            11.2.2. Guanylate Cyclase-C Agonist

                11.2.2.1. Plecanatide

                11.2.2.2. Linaclotide

            11.2.3. Laxatives

                11.2.3.1. Sodium Picosulphate

                11.2.3.2. Polycarbophil

                11.2.3.3. Others

            11.2.4. Stimulants

                11.2.4.1. Bisacodyl

                11.2.4.2. Senokot

                11.2.4.3. Others

            11.2.5. Others

        11.3. Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

            11.3.1. Oral

            11.3.2. Rectal

        11.4. Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            11.4.1. Hospital Pharmacies

            11.4.2. Retail Pharmacies

            11.4.3. Online Pharmacies

        11.5. Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Spain

            11.5.5. Italy

            11.5.6. Rest of Europe

        11.6. Europe Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis

            11.6.1. By Drug Class

            11.6.2. By Route of Administration

            11.6.3. By Distribution Channel

            11.6.4. By Country/Sub-region

    12. Asia Pacific Chronic Idiopathic Constipation Treatment Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            12.2.1. Serotonin-4 (5-Ht4) Receptor Agonist

                12.2.1.1. Prucalopride

                12.2.1.2. Others

            12.2.2. Guanylate Cyclase-C Agonist

                12.2.2.1. Plecanatide

                12.2.2.2. Linaclotide

            12.2.3. Laxatives

                12.2.3.1. Sodium Picosulphate

                12.2.3.2. Polycarbophil

                12.2.3.3. Others

            12.2.4. Stimulants

                12.2.4.1. Bisacodyl

                12.2.4.2. Senokot

                12.2.4.3. Others

            12.2.5. Others

        12.3. Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

            12.3.1. Oral

            12.3.2. Rectal

        12.4. Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            12.4.1. Hospital Pharmacies

            12.4.2. Retail Pharmacies

            12.4.3. Online Pharmacies

        12.5. Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis

            12.6.1. By Drug Class

            12.6.2. By Route of Administration

            12.6.3. By Distribution Channel

            12.6.4. By Country/Sub-region

    13. Latin America Chronic Idiopathic Constipation Treatment Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            13.2.1. Serotonin-4 (5-Ht4) Receptor Agonist

                13.2.1.1. Prucalopride

                13.2.1.2. Others

            13.2.2. Guanylate Cyclase-C Agonist

                13.2.2.1. Plecanatide

                13.2.2.2. Linaclotide

            13.2.3. Laxatives

                13.2.3.1. Sodium Picosulphate

                13.2.3.2. Polycarbophil

                13.2.3.3. Others

            13.2.4. Stimulants

                13.2.4.1. Bisacodyl

                13.2.4.2. Senokot

                13.2.4.3. Others

            13.2.5. Others

        13.3. Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

            13.3.1. Oral

            13.3.2. Rectal

        13.4. Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            13.4.1. Hospital Pharmacies

            13.4.2. Retail Pharmacies

            13.4.3. Online Pharmacies

        13.5. Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Latin America Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis

            13.6.1. By Drug Class

            13.6.2. By Route of Administration

            13.6.3. By Distribution Channel

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

            14.2.1. Serotonin-4 (5-Ht4) Receptor Agonist

                14.2.1.1. Prucalopride

                14.2.1.2. Others

            14.2.2. Guanylate Cyclase-C Agonist

                14.2.2.1. Plecanatide

                14.2.2.2. Linaclotide

            14.2.3. Laxatives

                14.2.3.1. Sodium Picosulphate

                14.2.3.2. Polycarbophil

                14.2.3.3. Others

            14.2.4. Stimulants

                14.2.4.1. Bisacodyl

                14.2.4.2. Senokot

                14.2.4.3. Others

            14.2.5. Others

        14.3. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

            14.3.1. Oral

            14.3.2. Rectal

        14.4. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

            14.4.1. Hospital Pharmacies

            14.4.2. Retail Pharmacies

            14.4.3. Online Pharmacies

        14.5. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis

            14.6.1. By Drug Class

            14.6.2. By Route of Administration

            14.6.3. By Distribution Channel

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player – Competition Matrix (By Tier and Size of companies)

        15.2. Market Share Analysis/Ranking By Company (2019)

        15.3. Company Profiles

            15.3.1. Bayer AG

                15.3.1.1. Company Overview

                15.3.1.2. Company Financials

                15.3.1.3. Growth Strategies

                15.3.1.4. SWOT Analysis

            15.3.2. Allergan

                15.3.2.1. Company Overview

                15.3.2.2. Company Financials

                15.3.2.3. Growth Strategies

                15.3.2.4. SWOT Analysis

            15.3.3. Bausch Health

                15.3.3.1. Company Overview

                15.3.3.2. Company Financials

                15.3.3.3. Growth Strategies

                15.3.3.4. SWOT Analysis

            15.3.4. Sanofi

                15.3.4.1. Company Overview

                15.3.4.2. Company Financials

                15.3.4.3. Growth Strategies

                15.3.4.4. SWOT Analysis

            15.3.5. Takeda Pharmaceutical Company

                15.3.5.1. Company Overview

                15.3.5.2. Company Financials

                15.3.5.3. Growth Strategies

                15.3.5.4. SWOT Analysis

            15.3.6. SEBELA PHARMACEUTICALS

                15.3.6.1. Company Overview

                15.3.6.2. Growth Strategies

                15.3.6.3. SWOT Analysis

            15.3.7. Ironwood Pharmaceuticals, Inc.

                15.3.7.1. Company Overview

                15.3.7.2. Company Financials

                15.3.7.3. Growth Strategies

                15.3.7.4. SWOT Analysis

            15.3.8. Albireo Pharma, Inc.

                15.3.8.1. Company Overview

                15.3.8.2. Company Financials

                15.3.8.3. Growth Strategies

                15.3.8.4. SWOT Analysis

            15.3.9. Sucampo Pharmaceuticals, Inc. (Mallinckrodt)

                15.3.9.1. Company Overview

                15.3.9.2. Company Financials

                15.3.9.3. Growth Strategies

                15.3.9.4. SWOT Analysis

            15.3.10. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

                15.3.10.1. Company Overview

                15.3.10.2. Company Financials

                15.3.10.3. Growth Strategies

                15.3.10.4. SWOT Analysis

    List of Tables

    Table 01: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 02: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

    Table 03: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030

    Table 04: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030

    Table 05: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030

    Table 06: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

    Table 07: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 08: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030

    Table 09: North America Chronic Idiopathic Constipation Market Value (US$ Mn) Forecast, by Country, 2018–2030

    Table 10: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 11: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

    Table 12: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030

    Table 13: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030

    Table 14: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030

    Table 15: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

    Table 16: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 17: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 18: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 19: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

    Table 20: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030

    Table 21: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030

    Table 22: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030

    Table 23: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

    Table 24: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 25: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 26: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 27: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

    Table 28: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030

    Table 29: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030

    Table 30: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030

    Table 31: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

    Table 32: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 33: Latin America Chronic Idiopathic Constipation Market Value (US$ Mn) Forecast, by Country, 2018–2030

    Table 34: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 35: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

    Table 36: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030

    Table 37: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030

    Table 38: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030

    Table 39: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

    Table 40: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 41: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 42: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 43: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

    Table 44: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030

    Table 45: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030

    Table 46: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030

    Table 47: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

    Table 48: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    List of Figures

    Figure 01: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, 2018–2030

    Figure 02: Global Chronic Idiopathic Constipation Treatment Market Value Share, by Drug Class, 2019

    Figure 03: Global Chronic Idiopathic Constipation Treatment Market Value Share, by Route of Administration, 2019

    Figure 04: Global Chronic Idiopathic Constipation Treatment Market Value Share, by Distribution Channel, 2019

    Figure 05: Global Chronic Idiopathic Constipation Treatment Market Value Share, by Region, 2019

    Figure 06: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 07: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 08: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

    Figure 09: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Guanylate Cyclase-C Agonist, 2018–2030

    Figure 10: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Laxatives, 2018–2030

    Figure 11: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Stimulants, 2018–2030

    Figure 12: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Others, 2018–2030

    Figure 13: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Serotonin-4 (5-Ht4) Receptor Agonist, 2019 and 2030

    Figure 14: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Serotonin-4 (5-Ht4) Receptor Agonist, 2020–2030

    Figure 15: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Guanylate Cyclase-C Agonist, 2019 and 2030

    Figure 16: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Guanylate Cyclase-C Agonist, 2020–2030

    Figure 17: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Laxatives, 2019 and 2030

    Figure 18: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Laxatives, 2020–2030

    Figure 19: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Stimulants, 2019 and 2030

    Figure 20: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Stimulants, 2020–2030

    Figure 21: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Route of Administration, 2019 and 2030

    Figure 22: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Route of Administration, 2020–2030

    Figure 23: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Oral, 2018–2030

    Figure 24: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Rectal, 2018–2030

    Figure 25: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 26: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 27: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Hospital Pharmacies, 2018–2030

    Figure 28: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Retail Pharmacies, 2018–2030

    Figure 29: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Online Pharmacies, 2018–2030

    Figure 30: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Region, 2019 and 2030

    Figure 31: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Region

    Figure 32: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 33: North America Chronic Idiopathic Constipation Market Value Share (%), by Country, 2019 and 2030

    Figure 34: North America Chronic Idiopathic Constipation Market Attractiveness, by Country, 2020–2030

    Figure 35: North America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Drug Class, 2019 and 2030

    Figure 36: North America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class, 2020–2030

    Figure 37: North America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Route of Administration, 2019 and 2030

    Figure 38: North America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration, 2020–2030

    Figure 39: North America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

    Figure 40: North America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel, 2020–2030

    Figure 41: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 42: Europe Chronic Idiopathic Constipation Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

    Figure 43: Europe Chronic Idiopathic Constipation Treatment Market Attractiveness, by Country/Sub-region, 2020–2030

    Figure 44: Europe Chronic Idiopathic Constipation Treatment Market Value Share (%), by Drug Class, 2019 and 2030

    Figure 45: Europe Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class, 2020–2030

    Figure 46: Europe Chronic Idiopathic Constipation Treatment Market Value Share (%), by Route of Administration, 2019 and 2030

    Figure 47: Europe Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration, 2020–2030

    Figure 48: Europe Chronic Idiopathic Constipation Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

    Figure 49: Europe Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel, 2020–2030

    Figure 50: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 51: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

    Figure 52: Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness, by Country/Sub-region, 2020–2030

    Figure 53: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value Share (%), by Drug Class, 2019 and 2030

    Figure 54: Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class, 2020–2030

    Figure 55: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value Share (%), by Route of Administration, 2019 and 2030

    Figure 56: Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration, 2020–2030

    Figure 57: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

    Figure 58: Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel, 2020–2030

    Figure 59: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 60: Latin America Chronic Idiopathic Constipation Market Value Share (%), by Country/Sub-region, 2019 and 2030

    Figure 61: Latin America Chronic Idiopathic Constipation Market Attractiveness, by Country/Sub-region, 2020–2030

    Figure 62: Latin America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Drug Class, 2019 and 2030

    Figure 63: Latin America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class, 2020–2030

    Figure 64: Latin America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Route of Administration, 2019 and 2030

    Figure 65: Latin America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration, 2020–2030

    Figure 66: Latin America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

    Figure 67: Latin America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel, 2020–2030

    Figure 68: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 69: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

    Figure 70: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness, by Country/Sub-region, 2020–2030

    Figure 71: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value Share (%), by Drug Class, 2019 and 2030

    Figure 72: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class, 2020–2030

    Figure 73: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value Share (%), by Route of Administration, 2019 and 2030

    Figure 74: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration, 2020–2030

    Figure 75: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

    Figure 76: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Copyright © Transparency Market Research, Inc. All Rights reserved